Logo do repositório
 
Publicação

Serum dipeptidyl peptidase 4 : a predictor of disease activity and prognosis in inflammatory bowel disease

2020Artigo científico Acesso restrito
Ver registo simples
dc.contributor.authorPinto Lopes, Pedro
dc.contributor.authorAfonso, Joana
dc.contributor.authorPinto Lopes, Rui
dc.contributor.authorRocha, Cátia
dc.contributor.authorLago, Paula
dc.contributor.authorGonçalves, Raquel
dc.contributor.authorTavares de Sousa, Helena
dc.contributor.authorMacedo, Guilherme
dc.contributor.authorCamila Dias, Cláudia
dc.contributor.authorMagro, Fernando
dc.date.accessioned2020-10-28T12:09:09Z
dc.date.available2020-10-28T12:09:09Z
dc.date.issued2020
dc.description© 2020 Crohn’s & Colitis Foundation. Published by Oxford University Press. All rights reserved. This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model.pt_PT
dc.descriptionA correction has been published: Inflammatory Bowel Diseases, Volume 26, Issue 6, June 2020, Page e56, https://doi.org/10.1093/ibd/izaa058pt_PT
dc.description.abstractBackground: Serum dipeptidyl peptidase 4 (DPP-4) has drawn particular interest as a biomarker in inflammatory bowel disease (IBD), as this protease inactivates several peptides that participate in the inflammatory cascade. Methods: Two prospectively recruited cohorts consisting of 195 patients (101 had Crohn’s disease [CD] and 94 had ulcerative colitis [UC]) were evaluated using clinical indexes and followed up to assess for treatment escalation. Sixty-eight patients underwent endoscopic evaluation at baseline. In the second cohort of 46 biologically treated patients, treatment response was assessed. Serum DPP-4, C-reactive protein (CRP), and fecal calprotectin levels were quantified at baseline and during follow-up. Results: Median DPP-4 levels were significantly lower in active IBD patients when compared with remitters (CD: 1043 [831–1412] vs 1589 [1255–1956] ng/mL; P < 0.001; UC: 1317 [1058–1718] vs 1798 [1329–2305] ng/mL; P = 0.001) and healthy controls (2175 [1875–3371] ng/mL). In fact, DPP-4 was able to distinguish clinical and endoscopic activity from remission, with areas under the curve (AUC) of 0.81/0.93 (CD) and 0.71/0.79 (UC), along with the need for treatment escalation, with comparable AUCs of 0.79 (CD) and 0.77 (UC). Furthermore, DPP-4 levels were higher in responders to treatment and more pronounced among UC (1467 [1301–1641] vs 1211 [1011–1448] ng/mL; P < 0.001) than CD patients (1385 [1185–1592] vs 1134 [975–1469] ng/mL; P = 0.015). Conclusions: Our results suggest that serum DPP-4 can be used as a noninvasive biomarker of IBD activity and biological treatment response and a predictor of treatment escalation, particularly when combined with other biomarkers.pt_PT
dc.description.sponsorshipThis work was supported by the Portuguese IBD Study Group (Grupo de Estudo da Doença Inflamatória Intestinal [GEDII]) and a research grant from Janssen-Cilag Pharmaceuticals. C.R. would like to acknowledge funding from “Fundação para a Ciência e Tecnologia (FCT),” Portugal, under grant number PDE/BDE/114583/2016pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationInflammatory Bowel Diseases, Volume 26, Issue 11, November 2020, pp. 1707–1719pt_PT
dc.identifier.doi10.1093/ibd/izz319pt_PT
dc.identifier.eissn1536-4844
dc.identifier.issn1078-0998
dc.identifier.urihttp://hdl.handle.net/10451/44691
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherOxford University Presspt_PT
dc.relationNovo título: “Anti-drug Antibodies” Anti-TNF pharmacokinetics: In vitro model
dc.relation.publisherversionhttps://academic.oup.com/ibdjournalpt_PT
dc.subjectBiomarkerspt_PT
dc.subjectDipeptidyl peptidase 4pt_PT
dc.subjectInflammatory bowel diseasept_PT
dc.titleSerum dipeptidyl peptidase 4 : a predictor of disease activity and prognosis in inflammatory bowel diseasept_PT
dc.typejournal article
dspace.entity.typePublication
oaire.awardTitleNovo título: “Anti-drug Antibodies” Anti-TNF pharmacokinetics: In vitro model
oaire.awardURIinfo:eu-repo/grantAgreement/FCT//PDE%2FBDE%2F114583%2F2016/PT
oaire.citation.endPage1719pt_PT
oaire.citation.issue11pt_PT
oaire.citation.startPage1707pt_PT
oaire.citation.titleInflammatory Bowel Diseasespt_PT
oaire.citation.volume26pt_PT
person.familyNamePinto Lopes
person.familyNameAfonso
person.givenNamePedro
person.givenNameJoana
person.identifier.orcid0000-0001-8450-8642
person.identifier.orcid0000-0001-9941-0613
person.identifier.ridA-4395-2016
person.identifier.scopus-author-id35338892800
project.funder.identifierhttp://doi.org/10.13039/501100001871
project.funder.nameFundação para a Ciência e a Tecnologia
rcaap.rightsrestrictedAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublication9e9c2bcc-fd99-402e-ab9d-e3dda2d5f637
relation.isAuthorOfPublication7b999928-1a2d-435f-adf4-764aaccc9a4e
relation.isAuthorOfPublication.latestForDiscovery9e9c2bcc-fd99-402e-ab9d-e3dda2d5f637
relation.isProjectOfPublication4b777985-b651-476e-9f51-4960b5b4e98a
relation.isProjectOfPublication.latestForDiscovery4b777985-b651-476e-9f51-4960b5b4e98a

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
Serum_dipeptidyl_peptidase.pdf
Tamanho:
1.27 MB
Formato:
Adobe Portable Document Format
Ver/Abrir

Coleções

FM-ISAMB-Artigos em Revistas Internacionais